In subgroup adjusted analysis pooling studies with HER2+ patients [51, 110], breast cancer patients with high Ki-67 were significantly associated with better response in the neoadjuvant setting (OR 3.67; 95% CI 1.11–12.12; p=0.03). Here, ERBB2 is linked to breast carcinoma.